Paradigm Biopharmaceuticals

Sign up to get the latest news, announcements and updates from Paradigm delivered straight to your inbox, and be the first to hear as our research advances.

Home

About us

Pipeline

Clinical Trials

Peer-Reviewed Publications

Cardiovascular

Respiratory

Lysosomal Storage Diseases

Inflammatory Arthritis

Osteoarthritis

Our Board

Executive Team

Corporate Governance

Analyst Reports

Market Data

Webinars

Announcements

News & Videos

Contact

Archivo

Dr Boreham's Crucible - PAR Nov 7.pdf

Paradigm Biopharmaceuticals (ASX: PAR) was featured in Dr Boreham’s Crucible published by Biotech Daily on 7 November 2025. The article highlights the strong progress of Paradigm’s pivotal Phase 3 PARA_OA_012 trial for Zilosul® (injectable pentosan polysulfate sodium) in knee osteoarthritis, with patient recruitment advancing across sites in Australia, the United States.

The piece notes the growing public awareness of the program, strong patient engagement following national media coverage, and Paradigm’s expanded osteoarthritis portfolio through the addition of Pentacoxib™, an oral PPS + COX-2 inhibitor combination for earlier-stage disease. It also references the company’s strengthened financial position through its convertible note facility and ongoing disciplined execution toward the planned interim analysis in mid-2026.

The full article provides an independent overview of Paradigm’s clinical and corporate momentum as the Company advances its mission to transform the treatment landscape for osteoarthritis.

Shareholder Update – Media Coverage: Dr Boreham’s Crucible, Biotech Daily (7 November 2025)